Применение ингибитора PARP олапариба в клинической практике лечения рака яичников

1. Cancer Research UK. Cancer mortality for common cancers. 2011. http://www.cancerresearchuk.org
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11–30.
3. Raja FA, Chopra N, Ledermann JA. Optimal first-line treatment in ovarian cancer. Ann Oncol 2012; 23 (Suppl. 10): x118–27.
4. European Medicines Agency. Lynparza. International non-pro- prietary name: Olaparib. European public assessment report. 014. http://www.ema.europa.eu
5. Ledermann JA, Raja FA, Fotopoulou C et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl. 6): vi24–32.
6. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609–15.
7. Wiedemeyer WR, Beach JA, Karlan BY. Reversing platinum resistance in high-grade serous ovarian carcinoma: targeting BRCA and the homologous recombination system. Front Oncol 2014; 4: 34. DOI: 10.3389/fonc.2014.00034
8. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15 (8): 852–61.
9. Khalique S, Hook JM, Ledermann JA. Maintenance therapy in ovarian cancer. Curr Opin Oncol 2014; 26 (5): 521–8.
10. Garcia A, Singh H. Bevacizumab and ovarian cancer. Ther Adv Med Oncol 2013; 5 (2): 133–41.
11. Chen Y, Zhang L, Hao Q. Olaparib: a promising PARP inhibitor in ovarian cancer therapy. Arch Gynecol Obstet 2013; 288 (2): 367–74.
12. Shaw HM, Hall M. Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib. Onco Targets Ther 2013; 6: 1197–206.
13. Lheureux S, Oza AM. Olaparib for the treatment of ovarian cancer. Expert Opin Orphan Drugs 2014; 2 (5): 497–508.
14. Basu B, Sandhu SK, de Bono JS. PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer. Drugs 2012; 72 (12): 1579–90.
15. De Lorenzo SB, Patel AG, Hurley RM et al. The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells. Front Oncol 2013; 3: 228. DOI: 10.3389/fonc.2013.00228.
16. Lee JM, Ledermann JA, Kohn EC. PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol 2014; 25 (1): 32–40.
17. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008; 26 (22): 3785–90.
18. Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med 2013; 19: 1381–8.
19. Press JZ, de Luca A, Boyd N et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008; 8: 17. DOI: 10.1186/1471-2407-8-17.
20. Alsop K, Fereday S, Meldrum C et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012; 30: 2654–63.
21. Beristain E, Martínez-Bouzas C, Guerra I et al. Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counseling. Breast Cancer Res Treatment 2007; 106 (2): 255–62.
22. Frank TS, Deffenbaugh AM, Reid JE et al. Clinical char- acteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002; 20 (6): 1480–90.
23. Konecny M, Milly M, Zavodna K et al. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia. Breast Cancer Res Treatment 2011; 126 (1): 119–30.
24. Marroni F, Aretini P, D’Andre E et al. Penetrances of breast and ovarian cancer in a large series of families tested BRCA1/2 mutations. Eur J Hum Genet 2004; 12 (11): 899–906.
25. Nanda R, Schumm LP, Cummings S et al. Genetictestingin an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. J Am Med Assoc 2005; 294 (15): 1925–33.
26. Seymour IJ, Casadei S, Zampiga V et al. Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations. Breast Cancer Res Treatment 2008; 112 (2): 343–9.
27. Weitzel JN, Lagos V, Blazer KR et al. Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol, Biomarkers Prevent 2005; 14 (7): 1666–71.
28. Gayther SA, Russell P, Harrington P et al. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet 1999; 65 (4): 1021–9.
29. Anton-Culver H, Cohen PP, Gildea ME, Ziogas A. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur J Cancer 2000; 36 (10): 1200–8.
30. Janezic SA, Ziogas A, Krumroy LM et al. Germline BRCA1 alterations in a population-based series of ovarian cancer cases. Hum Molecular Genet 1999; 8 (5): 889–97.
31. Risch HA, McLaughlin JR, Cole DEC et al. Population BRCA1 and BRCA2 mutation frequencies and cancer pene-trances: a kin-cohort study in Ontario, Canada. J Nat Cancer Institute 2006; 98 (23): 1694–706.
32. Stratton JF, Gayther SA, Russell P et al. Contribution of BRCA1 mutations to ovarian cancer. New Engl J Med 1997; 336 (16): 1125–30.
33. Alsop K, Fereday S, Meldrum C et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group. J Clin Oncol 2012; 30 (21): 2654–63.
34. Zhang S, Royer R, Li S et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 2011; 121 (2): 353–7.
35. Stavropoulou AV, Fostira F, Pertesi M et al. Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases. PLoS ONE 2013; 8 (3).
36. De Leeneer K, Coene I, Crombez B et al. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing. Breast Cancer Res Treatment 2012; 132 (1): 87–95.
37. Brozek I, Ochman K, Debniak J et al. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland. Gynecol Oncol 2008; 108 (2): 433–7.
38. Smirnova TY, Pospekhova NI, Lyubchenko LN et al. High incidence of mutations in BRCA1 and BRCA2 genes in ovarian cancer. Bul Experimental Biol Med 2007; 144 (1): 83–5.
39. Lim MC, Kang S, Seo S et al. BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients. J Cancer Res Clin Oncol 2009; 135 (11): 1593–9.
40. Boyd J, Sonoda Y, Federici MG et al. Clinicopatholic features of BRCA-linked and sporadic ovarian cancer. J Am Medl Assoc 2000; 283 (17): 2260–5.
41. Berchuck A, Heron K, Carney ME et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 1998; 4 (10): 2433–7.
42. Lakhani SR, Manek S, Penault-Llorca F et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004; 10 (7): 2473–81.
43. Rubin SC, Benjamin I, Behbakht K et al. Clinical and pathological features of ovarian cancer in women with germline mutations of BRCA1. New Engl J Med 1996; 335 (19): 1413–6.
44. Shaw PA, McLaughlin JR, Zweemer RP et al. Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol 2002; 21 (4): 407–11.
45. Werness BA, Ramus SJ, Whittemore AS et al. Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. Hum Pathol 2000; 31 (11): 1420–4.
46. Mavaddat N, Barrowdale D, Andrulis IL et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prevention 2012; 21 (1): 134–47.
47. Safra T, Borgato L, Nicoletto MO et al. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. Mol Cancer Ther 2011; 10: 2000–7.
48. Adams SF, Marsh EB, Elmasri W et al. A high response liposomal doxorubicin is seen among women with BRCA mutations treated for re- current epithelial ovarian cancer. Gynecol Oncol 2011; 123: 486–91.
49. Kaye SB, Lubinski J, Matulonis U et al. Phase II, open-label, random- ized, multicenter study comparing the effıcacy and safety of olaparib, a poly(ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012; 30: 372–9.
50. Tewey KM, Rowe TC, Yang L et al. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226: 466–8.
51. Hyman DM, Zhou Q, Arnold AG et al. Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol 2011; 123: 196–9.
52. Safra T, Rogowski O, Muggia FM. The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer. Int J Gynecol Cancer 2014; 24: 488–95.
53. Rose PG. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 2005; 10: 205–14.
54. Thorn CF, Oshiro C, Marsh S et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 2011; 21: 440–6.
55. David SP, Tan DS, Kaye SB. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different? ASCO EDUCATIONAL BOOK 2015; p. 114–2.
56. Baird RD, Tan DS, Kaye SB. Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat Rev Clin Oncol 2010; 7: 575–82.
57. Quinn JE, Carser JE, James CR et al. BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol Oncol 2009; 113: 134–42.
58. Chabalier C, Lamare C, Racca C et al. BRCA1 down regulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 2006; 5: 1001–7.
59. Tan DS, Yap TA, Hutka M et al. Implications of BRCA1 and BRCA2 mutations for the effıcacy of paclitaxel monotherapy in advanced ovarian cancer. Eur J Cancer 2013; 49: 1246–53.
60. Tassone P, Tagliaferri P, Perricelli A et al.  BRCA expression modulates  chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer. 2003; 88: 1285–91.
61. Zhou C, Smith JL, Liu J. Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 2003; 22: 2396–404.
62. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361 (2): 123–34.
63. Fong PC, Yap TA, Boss DS et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28 (15): 2512–9.
64. Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376 (9737): 245–51.
65. Kaufman B, Shapira-Frommer R, Schmutzler RK et al. Olaparib monotherapy in patients. Curr Oncol Rep (2016) 18:29 with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015; 33 (3): 244–50.
66. Domchek SM, Aghajanian C, Shapira-Frommer R et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol 2016; 140 (2): 199–203.
67. Lee JM, Hays JL, Annunziata CM et al. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst 2014; 106 (6): dju089. Pubmed Central PMCID: 4049120.
68. Oza AM, Cibula D, Benzaquen AO et al. Olaparib combined with chemotherapy for recur- rent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 2015; 16 (1): 87–97.
69. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinum-sensitive re-lapsed ovarian cancer. N Engl J Med 2012; 366 (15): 1382–92.
70. Jonathan A Ledermann, Philipp Harter. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol 2016; 17: 1579–89.
71. Jonathan A Ledermann, Philipp Harter et al. Quality of life during olaparib maintenance  therapy in platinum-sensitive relapsed serous  ovarian cancer. Br J Cancer 2016; 1–8. DOI: 10.1038/bjc. 2016.348.
72. Kathleen N Moore, Bradley J Monk. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer. Oncologist 2016; 21: 1–10.
73. Michael Friedlander, Susana Banerjee. Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer. Asia-Pacific J Clin Oncol 2016; 12: 323–31.
74. Jonathan A Ledermann, Sessa C et al. eUpdate-Ovarian cancer treatment recommendations. ESMO 2016.
75. Тюляндин С.А., Деньгина Н.В., Коломиец Л.А. и др. Практические рекомендации по лекарственному лечению рака яичников/ первичного рака брюшины/рака маточных труб. Злокачественные опухоли. 2016; 4 (Спецвып. 2): 123–34. / Tiulyandin S.A., Dengina N.V., Kolomiets L.A. i dr. Prakticheskie rekomendatsii po lekarstvennomu lecheniiu raka iaichnikov/pervichnogo raka briushiny/raka matochnykh trub. Zlokachestvennye opukholi. 2016; 4 (Spetsvyp. 2): 123–34. [in Russian]

________________________________________________

1. Cancer Research UK. Cancer mortality for common cancers. 2011. http://www.cancerresearchuk.org
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11–30.
3. Raja FA, Chopra N, Ledermann JA. Optimal first-line treatment in ovarian cancer. Ann Oncol 2012; 23 (Suppl. 10): x118–27.
4. European Medicines Agency. Lynparza. International non-pro- prietary name: Olaparib. European public assessment report. 014. http://www.ema.europa.eu
5. Ledermann JA, Raja FA, Fotopoulou C et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl. 6): vi24–32.
6. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609–15.
7. Wiedemeyer WR, Beach JA, Karlan BY. Reversing platinum resistance in high-grade serous ovarian carcinoma: targeting BRCA and the homologous recombination system. Front Oncol 2014; 4: 34. DOI: 10.3389/fonc.2014.00034
8. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15 (8): 852–61.
9. Khalique S, Hook JM, Ledermann JA. Maintenance therapy in ovarian cancer. Curr Opin Oncol 2014; 26 (5): 521–8.
10. Garcia A, Singh H. Bevacizumab and ovarian cancer. Ther Adv Med Oncol 2013; 5 (2): 133–41.
11. Chen Y, Zhang L, Hao Q. Olaparib: a promising PARP inhibitor in ovarian cancer therapy. Arch Gynecol Obstet 2013; 288 (2): 367–74.
12. Shaw HM, Hall M. Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib. Onco Targets Ther 2013; 6: 1197–206.
13. Lheureux S, Oza AM. Olaparib for the treatment of ovarian cancer. Expert Opin Orphan Drugs 2014; 2 (5): 497–508.
14. Basu B, Sandhu SK, de Bono JS. PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer. Drugs 2012; 72 (12): 1579–90.
15. De Lorenzo SB, Patel AG, Hurley RM et al. The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells. Front Oncol 2013; 3: 228. DOI: 10.3389/fonc.2013.00228.
16. Lee JM, Ledermann JA, Kohn EC. PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol 2014; 25 (1): 32–40.
17. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008; 26 (22): 3785–90.
18. Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med 2013; 19: 1381–8.
19. Press JZ, de Luca A, Boyd N et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008; 8: 17. DOI: 10.1186/1471-2407-8-17.
20. Alsop K, Fereday S, Meldrum C et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012; 30: 2654–63.
21. Beristain E, Martínez-Bouzas C, Guerra I et al. Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counseling. Breast Cancer Res Treatment 2007; 106 (2): 255–62.
22. Frank TS, Deffenbaugh AM, Reid JE et al. Clinical char- acteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002; 20 (6): 1480–90.
23. Konecny M, Milly M, Zavodna K et al. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia. Breast Cancer Res Treatment 2011; 126 (1): 119–30.
24. Marroni F, Aretini P, D’Andre E et al. Penetrances of breast and ovarian cancer in a large series of families tested BRCA1/2 mutations. Eur J Hum Genet 2004; 12 (11): 899–906.
25. Nanda R, Schumm LP, Cummings S et al. Genetictestingin an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. J Am Med Assoc 2005; 294 (15): 1925–33.
26. Seymour IJ, Casadei S, Zampiga V et al. Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations. Breast Cancer Res Treatment 2008; 112 (2): 343–9.
27. Weitzel JN, Lagos V, Blazer KR et al. Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol, Biomarkers Prevent 2005; 14 (7): 1666–71.
28. Gayther SA, Russell P, Harrington P et al. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet 1999; 65 (4): 1021–9.
29. Anton-Culver H, Cohen PP, Gildea ME, Ziogas A. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur J Cancer 2000; 36 (10): 1200–8.
30. Janezic SA, Ziogas A, Krumroy LM et al. Germline BRCA1 alterations in a population-based series of ovarian cancer cases. Hum Molecular Genet 1999; 8 (5): 889–97.
31. Risch HA, McLaughlin JR, Cole DEC et al. Population BRCA1 and BRCA2 mutation frequencies and cancer pene-trances: a kin-cohort study in Ontario, Canada. J Nat Cancer Institute 2006; 98 (23): 1694–706.
32. Stratton JF, Gayther SA, Russell P et al. Contribution of BRCA1 mutations to ovarian cancer. New Engl J Med 1997; 336 (16): 1125–30.
33. Alsop K, Fereday S, Meldrum C et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group. J Clin Oncol 2012; 30 (21): 2654–63.
34. Zhang S, Royer R, Li S et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 2011; 121 (2): 353–7.
35. Stavropoulou AV, Fostira F, Pertesi M et al. Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases. PLoS ONE 2013; 8 (3).
36. De Leeneer K, Coene I, Crombez B et al. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing. Breast Cancer Res Treatment 2012; 132 (1): 87–95.
37. Brozek I, Ochman K, Debniak J et al. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland. Gynecol Oncol 2008; 108 (2): 433–7.
38. Smirnova TY, Pospekhova NI, Lyubchenko LN et al. High incidence of mutations in BRCA1 and BRCA2 genes in ovarian cancer. Bul Experimental Biol Med 2007; 144 (1): 83–5.
39. Lim MC, Kang S, Seo S et al. BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients. J Cancer Res Clin Oncol 2009; 135 (11): 1593–9.
40. Boyd J, Sonoda Y, Federici MG et al. Clinicopatholic features of BRCA-linked and sporadic ovarian cancer. J Am Medl Assoc 2000; 283 (17): 2260–5.
41. Berchuck A, Heron K, Carney ME et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 1998; 4 (10): 2433–7.
42. Lakhani SR, Manek S, Penault-Llorca F et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004; 10 (7): 2473–81.
43. Rubin SC, Benjamin I, Behbakht K et al. Clinical and pathological features of ovarian cancer in women with germline mutations of BRCA1. New Engl J Med 1996; 335 (19): 1413–6.
44. Shaw PA, McLaughlin JR, Zweemer RP et al. Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol 2002; 21 (4): 407–11.
45. Werness BA, Ramus SJ, Whittemore AS et al. Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. Hum Pathol 2000; 31 (11): 1420–4.
46. Mavaddat N, Barrowdale D, Andrulis IL et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prevention 2012; 21 (1): 134–47.
47. Safra T, Borgato L, Nicoletto MO et al. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. Mol Cancer Ther 2011; 10: 2000–7.
48. Adams SF, Marsh EB, Elmasri W et al. A high response liposomal doxorubicin is seen among women with BRCA mutations treated for re- current epithelial ovarian cancer. Gynecol Oncol 2011; 123: 486–91.
49. Kaye SB, Lubinski J, Matulonis U et al. Phase II, open-label, random- ized, multicenter study comparing the effıcacy and safety of olaparib, a poly(ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012; 30: 372–9.
50. Tewey KM, Rowe TC, Yang L et al. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226: 466–8.
51. Hyman DM, Zhou Q, Arnold AG et al. Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol 2011; 123: 196–9.
52. Safra T, Rogowski O, Muggia FM. The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer. Int J Gynecol Cancer 2014; 24: 488–95.
53. Rose PG. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 2005; 10: 205–14.
54. Thorn CF, Oshiro C, Marsh S et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 2011; 21: 440–6.
55. David SP, Tan DS, Kaye SB. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different? ASCO EDUCATIONAL BOOK 2015; p. 114–2.
56. Baird RD, Tan DS, Kaye SB. Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat Rev Clin Oncol 2010; 7: 575–82.
57. Quinn JE, Carser JE, James CR et al. BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol Oncol 2009; 113: 134–42.
58. Chabalier C, Lamare C, Racca C et al. BRCA1 down regulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 2006; 5: 1001–7.
59. Tan DS, Yap TA, Hutka M et al. Implications of BRCA1 and BRCA2 mutations for the effıcacy of paclitaxel monotherapy in advanced ovarian cancer. Eur J Cancer 2013; 49: 1246–53.
60. Tassone P, Tagliaferri P, Perricelli A et al.  BRCA expression modulates  chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer. 2003; 88: 1285–91.
61. Zhou C, Smith JL, Liu J. Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 2003; 22: 2396–404.
62. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361 (2): 123–34.
63. Fong PC, Yap TA, Boss DS et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28 (15): 2512–9.
64. Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376 (9737): 245–51.
65. Kaufman B, Shapira-Frommer R, Schmutzler RK et al. Olaparib monotherapy in patients. Curr Oncol Rep (2016) 18:29 with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015; 33 (3): 244–50.
66. Domchek SM, Aghajanian C, Shapira-Frommer R et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol 2016; 140 (2): 199–203.
67. Lee JM, Hays JL, Annunziata CM et al. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst 2014; 106 (6): dju089. Pubmed Central PMCID: 4049120.
68. Oza AM, Cibula D, Benzaquen AO et al. Olaparib combined with chemotherapy for recur- rent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 2015; 16 (1): 87–97.
69. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinum-sensitive re-lapsed ovarian cancer. N Engl J Med 2012; 366 (15): 1382–92.
70. Jonathan A Ledermann, Philipp Harter. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol 2016; 17: 1579–89.
71. Jonathan A Ledermann, Philipp Harter et al. Quality of life during olaparib maintenance  therapy in platinum-sensitive relapsed serous  ovarian cancer. Br J Cancer 2016; 1–8. DOI: 10.1038/bjc. 2016.348.
72. Kathleen N Moore, Bradley J Monk. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer. Oncologist 2016; 21: 1–10.
73. Michael Friedlander, Susana Banerjee. Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer. Asia-Pacific J Clin Oncol 2016; 12: 323–31.
74. Jonathan A Ledermann, Sessa C et al. eUpdate-Ovarian cancer treatment recommendations. ESMO 2016.
75. Tiulyandin S.A., Dengina N.V., Kolomiets L.A. i dr. Prakticheskie rekomendatsii po lekarstvennomu lecheniiu raka iaichnikov/pervichnogo raka briushiny/raka matochnykh trub. Zlokachestvennye opukholi. 2016; 4 (Spetsvyp. 2): 123–34. [in Russian]

С.В.Хохлова*

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России.
115478, Россия, Москва, Каширское ш., д. 23
*svkhokhlova@mail.ru

________________________________________________

S.V.Khokhlova*

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
*svkhokhlova@mail.ru